PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17015054-0	2006	MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine.	Mefloquine	80-90	ATP binding cassette subfamily B member 1	Homo sapiens	0-4	
17015054-2	2006	We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.	Mefloquine	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	109-113	
17015054-2	2006	We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.	Mefloquine	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	114-119	
17015054-2	2006	We hypothesized that neuropsychiatric adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene that encodes for the efflux pump P-glycoprotein.	Mefloquine	57-67	ATP binding cassette subfamily B member 1	Homo sapiens	158-172	
17015054-9	2006	CONCLUSION: In this study the MDR1 1236TT, 2677TT, and 3435TT genotypes, along with the 1236-2677-3435 TTT haplotype, were associated with neuropsychiatric adverse effects of mefloquine in women.	Mefloquine	175-185	ATP binding cassette subfamily B member 1	Homo sapiens	30-34	
17015054-10	2006	MDR1 polymorphisms may play an important role in predicting the occurrence of neuropsychiatric adverse effects of mefloquine, particularly in female travelers.	Mefloquine	114-124	ATP binding cassette subfamily B member 1	Homo sapiens	0-4